The regulatory requirement is to "demonstrate the essential requirements of safety and performance have been achieved".
Demonstrating safety alone is, in my experience, very unlikely to suffice. The regulators simply favour approved devices over unapproved devices for which performance has not been scientifically proven via RCT.
The Aus CT / IDE results, if successful, could potentially facilitate the CE approval process.
- Forums
- ASX - By Stock
- To The Naysayers
OSL
oncosil medical ltd
Add to My Watchlist
5.69%
!
$1.16

The regulatory requirement is to "demonstrate the essential...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$1.16 |
Change
-0.070(5.69%) |
Mkt cap ! $16.49M |
Open | High | Low | Value | Volume |
$1.25 | $1.25 | $1.11 | $72.36K | 60.96K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 9286 | $1.16 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.18 | 412 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 9286 | 1.160 |
1 | 2126 | 1.150 |
1 | 7500 | 1.080 |
2 | 19761 | 1.050 |
1 | 2500 | 1.030 |
Price($) | Vol. | No. |
---|---|---|
1.180 | 412 | 1 |
1.200 | 8677 | 1 |
1.245 | 2418 | 1 |
1.250 | 46027 | 1 |
1.300 | 1500 | 1 |
Last trade - 16.10pm 27/06/2025 (20 minute delay) ? |
Featured News
OSL (ASX) Chart |
The Watchlist
PAR
PARADIGM BIOPHARMACEUTICALS LIMITED..
Paul Rennie, MD & Founder
Paul Rennie
MD & Founder
SPONSORED BY The Market Online